| 摘要 |
<p>The present invention relates to a pharmaceutical composition comprising glucocorticoid (GC)-induced human monocytes, and optionally a pharmaceutically acceptable carrier. The present invention further relates to a pharmaceutical composition comprising GC and optionally a pharmaceutically acceptable carrier, for use in the treatment of a disease which is GC-responsive, wherein said pharmaceutical composition is to be administered to human monocytes ex vivo. The pharmaceutical composition may be used for treatment of a disease which is GC-responsive. In another aspect, the present invention relates to the use of GC for the preparation of a pharmaceutical composition for the treatment of a patient in need of a GC-therapy, wherein said GC is to be administered to monocytes of said patient ex vivo. In a further embodiment, the present invention relates to a method for the preparation of a pharmaceutical composition comprising the step of contacting human monocytes ex vivo with a GC. A teflon container (e.g. a teflon bag) comprising a glucocorticoid and optionally a colony-stimulating factor (CSF) is also envisaged. In an even further embodiment, the present invention relates to a method of screening for a compound which is suitable for the treatment of a GC-responsive disease, said method comprising: a) contacting a monocyte with a compound to be tested; b) evaluating whether the monocyte is GC-induced; and thereby, c) identifying compounds which are suitable for the treatment of a GC-responsive disease.</p> |
